Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT02708511
Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer
Overview
This pilot clinical trial studies copper Cu 64-DOTA-B-Fab positron emission tomography (PET)/computed tomography (CT) in imaging patients with ovarian and breast cancer. Cancer antigen (CA)6 is an antigen (substance) found on the surface of several types of cancer cells such as cancer of the ovary and breast. Diagnostic procedures, such as copper Cu 64-DOTA-B-Fab PET/CT, may help identify CA6 positive tumors and allow doctors to plan better treatment.
Sponsor
Stanford University
Phase
Phase 1
Contacts
Sanjiv Gambhir (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT02708511Drug / Compound
B-Fab
Isotope(s):
COPPER-64
Radioisotope: Cu-64
Theranostic Role: PET Imaging
T1/2 (Half-Life): 12.7 Hours
Decay Mode: POSITRON β+, BETA, Electron Capture, GAMMA
Energy: 0.65 MeV, Gamma 511 keV
Range: max 2.5mm, mean 0.7mm
Decay Daughters: Ni64 (Stable), Zn64 (Stable)
Status: FDA Approval: DETECTNET®
Target(s):
- No Explicit Target
Ligand Class: Small Proteins and Antibody Fragments
Chelator: DOTA
Eligibility
Inclusion
- Participant has biopsy proven breast cancer and may or may not undergo surgical excision of the cancerous lesion(s)
- Participant has suspected or biopsy proven ovarian cancer and is scheduled to undergo surgical excision of the cancerous lesion(s) OR Participant has biopsy proven ovarian cancer but is not a surgical candidate
- Patient is able to remain still for duration of each imaging procedure
- Patient is able to remain still for duration of each imaging procedureBreast Cancer Participants
- Ovarian Cancer Participants
Exclusion
- Patient is pregnant or breast-feeding
- Patients participating in other research imaging protocols will be excluded from this study.
- Patients with serious uncontrolled concurrent medical illness that would limit compliance with study requirements
- Patients participating in other research imaging protocols will be excluded from this study.Breast Cancer Participants
- Patient is pregnant or breast-feeding
- Patients with serious uncontrolled concurrent medical illness that would limit compliance with study requirements
- Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or other study procedures.
- Patients with contraindications for PET/CT or who cannot complete a PET/CT scan or other study procedures.
- Ovarian Cancer Participants
Share your feedback
Help us improve your experience